Session Information

WCLC 2019

2019 World Conference on Lung Cancer

Conference Program for the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):
- Sept 7 - 10, 2019
- Total Presentations: 2970
Register to Attend WCLC Return to WCLC 2019 Website Download Program (PDF) Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
September 7 Sat
Sep 7 Sunday
September 8 Sun
Sep 8 Monday
September 9 Mon
Sep 9 Tuesday
September 10 Tue
Sep 10

Filter Results:

Show Only CME Accredited Sessions

29911

+
MA01 - Oligometastatic Disease
- 10:30 - 12:00
- 9/08/2019
- Location: Copenhagen (1980)
- IASLC CME Accredited
- Type: Mini Oral Session
- Track: Oligometastatic NSCLC
- Moderators:Anne Marie Clasina Dingemans, Matthias Guckenberger
- 29918
  
  +
  
  MA01.09 - Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study
  
  11:30 - 11:35 | Presenter: Li Zhang | Author(s): Ping Peng, Yongshun Chen, Guang Han, Rui Meng, Sheng Zhang, Zhengkai Liao, Yujie Zhang, Juejun Gong, Chuangying Xiao, Xiyou Liu, Peng Zhang, Lu Zhang, Shu Xia, Qian Chu, Yuan Chen
  Abstract
  
  Loading...
30064

+
MA10 - Emerging Technologies for Lung Cancer Detection
- 15:15 - 16:45
- 9/08/2019
- Location: Dublin (1997)
- IASLC CME Accredited
- Type: Mini Oral Session
- Track: Screening and Early Detection
- Moderators:Fabrizio Bianchi, Marcelo Sanchez
- 30066
  
  +
  
  MA10.02 - Deep Learning with Radiomics May Predict High-Grade Lung Adenocarcinoma Based on Histological Patterns in Ground Glass Opacity Lesions
  
  15:20 - 15:25 | Presenter: Xing Wang | Author(s): Li Zhang, Lei Tang, Xin Yang, Quanzheng Li, Nan Wu
  Abstract
  
  Loading...
32148

+
EP1.14 - Targeted Therapy
- 08:00 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- 32173
  
  +
  
  EP1.14-20 - EGFR T790M Mutated Cells Are Not a New Emerging Sub-Clonal Population in Lung Adenocarcinoma After the Treatment of Targeted Therapy
  
  08:00 - 08:00 | Presenter: xiaohua Shi | Author(s): shafei Wu, Yuanyuan Liu, xIAODING Liu, hanping Wang, Li Zhang, zhiyong Liang, xuan Zeng
  Abstract
  
  Loading...
30446

+
P1.01 - Advanced NSCLC
- 09:45 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- 30484
  
  +
  
  P1.01-31 - Evaluating Engineered Heme-Sequestering Peptides for Treating Non-Small Cell Lung Cancer Orthotopic Tumor Model Using Multi-Modality Imaging
  
  09:45 - 09:45 | Presenter: Li Liu | Author(s): Shigen Zhong, Jingyu Chen, James Campbell, Jeni Gerberich, Guiyang Hao, Li Zhang
  Abstract
  
  Loading...
31237

+
P1.10 - Prevention and Tobacco Control
- 09:45 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Prevention and Tobacco Control
- 31240
  
  +
  
  P1.10-03 - Gut Microbiota and Lung Cancer: A Mendelian Randomisation Study
  
  09:45 - 09:45 | Presenter: Huaqiang Zhou | Author(s): Jiaqing Liu, Yaxiong Zhang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Yan Huang, Li Zhang
  Abstract
  
  Loading...
31272

+
P1.11 - Screening and Early Detection
- 09:45 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Screening and Early Detection
- 31285
  
  +
  
  P1.11-09 - Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database
  
  09:45 - 09:45 | Presenter: Jiayi Shen | Author(s): Huaqiang Zhou, Yaxiong Zhang, Yan Huang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Gang Chen, Shen Zhao, Xi Chen, Zhonghan Zhang, Jiaqing Liu, Wei Xian, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Hongyun Zhao, Li Zhang
  Abstract
  
  Loading...
30117

+
MA11 - Immunotherapy in Special Populations and Predictive Markers
- 14:00 - 15:30
- 9/09/2019
- Location: Hilton Head (1978)
- IASLC CME Accredited
- Type: Mini Oral Session
- Track: Immuno-oncology
- Moderators:Frank Griesinger, Lecia Sequist
- 30119
  
  +
  
  MA11.02 - KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
  
  14:05 - 14:10 | Presenter: Yi-Long Wu | Author(s): Li Zhang, Yun Fan, Jianying Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, Gongyan Chen, Xin Zhang, Caicun Zhou, Thao Dang, Justina Penrod, Debra A. Kush, Yun Qin, Ben Li, Tony Mok
  Abstract
  
  Loading...
30148

+
MA12 - New Frontiers from Pathology to Genomics
- 14:00 - 15:30
- 9/09/2019
- Location: Melbourne (1991)
- IASLC CME Accredited
- Type: Mini Oral Session
- Track: Mesothelioma
- Moderators:Prasad S Adusumilli, Francisco Perez Ochoa
- 30151
  
  +
  
  MA12.03 - PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells
  
  14:10 - 14:15 | Presenter: Raffit Hassan | Author(s): Daniel Rathkey, Manakamana Khanal, Junko Murai, Jingli Zhang, Qun Jiang, Betsy Morrow, Christine Evans, Raj Chari, Manjistha Sengupta, Anish Thomas, Yves Pommier
  Abstract
  
  Loading...
- 30157
  
  +
  
  MA12.11 - Anti-Tumor Efficacy of Mesothelin Targeted Immunotoxin LMB-100 Plus Pembrolizumab in Mesothelioma Patients and Mouse Models
  
  15:10 - 15:15 | Presenter: Raffit Hassan | Author(s): Qun Jiang, Azam Ghafoor, Daniel Rathkey, Idrees Mian, Jingli Zhang, Betsy Morrow, Ira Pastan
  Abstract
  
  Loading...
30943

+
P2.04 - Immuno-oncology
- 10:15 - 18:15
- 9/09/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- 30954
  
  +
  
  P2.04-13 - Interleukin-18 and Lung Cancer: A Mendelian Randomization Study
  
  10:15 - 10:15 | Presenter: Jiaqing Liu | Author(s): Huaqiang Zhou, Yaxiong Zhang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Gang Chen, Shen Zhao, Zhonghan Zhang, Jiayi Shen, Wei Xian, Yan Huang, Hongyun Zhao, Li Zhang
  Abstract
  
  Loading...
- 30959
  
  +
  
  P2.04-17 - Immune Repertoire Is a Potential Predictive Biomarker for Evaluating the Efficacy of Mutant Neoantigen Specific T Cell Combined with PD1 Antibody
  
  10:15 - 10:15 | Presenter: Qi Song | Author(s): Jing Li, Tianfu Zhang, Zishan Zhou, Yujie Song, Shengjie Sun, Boyu Qin, Jinliang Wang, Li Zhang, Xiaoling Zhang, Dan Wang, Meiling Chen, Jin Li, Shunchang Jiao
  Abstract
  
  Loading...
32410

+
MA25 - Precision Medicine in Advanced NSCLC
- 14:30 - 16:00
- 9/10/2019
- Location: Dublin (1997)
- IASLC CME Accredited
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Moderators:Sebastian Defranchi, Karen Kelly
- 32413
  
  +
  
  MA25.09 - Navigating Anlotinib Precision Therapy Through the Genetic Profiling of Circulating DNA in Non-Small Cell Lung Cancer Patients
  
  15:29 - 15:36 | Presenter: Jun Lu | Author(s): Hua Zhong, Jun Wu, Tianqing Chu, Lele Zhang, Hua Li, Qiming Wang, Rong Li, Yizhuo Zhao, Aiqin Gu, Chunlei Shi, Liwen Xiong, Xueyan Zhang, Wei Zhang, Yuqing Lou, Bo Yan, Yu Dong, Yanwei Zhang, Baolan Li, Li Zhang, Xiaodong Zhao, Kai Li, Baohui Han
  Abstract
  
  Loading...

Session Information

WCLC 2019

2019 World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

MA01 - Oligometastatic Disease

+

MA01.09 - Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study

+

MA10 - Emerging Technologies for Lung Cancer Detection

+

MA10.02 - Deep Learning with Radiomics May Predict High-Grade Lung Adenocarcinoma Based on Histological Patterns in Ground Glass Opacity Lesions

+

EP1.14 - Targeted Therapy

+

EP1.14-20 - EGFR T790M Mutated Cells Are Not a New Emerging Sub-Clonal Population in Lung Adenocarcinoma After the Treatment of Targeted Therapy

+

P1.01 - Advanced NSCLC

+

P1.01-31 - Evaluating Engineered Heme-Sequestering Peptides for Treating Non-Small Cell Lung Cancer Orthotopic Tumor Model Using Multi-Modality Imaging

+

P1.10 - Prevention and Tobacco Control

+

P1.10-03 - Gut Microbiota and Lung Cancer: A Mendelian Randomisation Study

+

P1.11 - Screening and Early Detection

+

P1.11-09 - Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database

+

MA11 - Immunotherapy in Special Populations and Predictive Markers

+

MA11.02 - KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%

+

MA12 - New Frontiers from Pathology to Genomics

+

MA12.03 - PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells

+

MA12.11 - Anti-Tumor Efficacy of Mesothelin Targeted Immunotoxin LMB-100 Plus Pembrolizumab in Mesothelioma Patients and Mouse Models

+

P2.04 - Immuno-oncology

+

P2.04-13 - Interleukin-18 and Lung Cancer: A Mendelian Randomization Study

+

P2.04-17 - Immune Repertoire Is a Potential Predictive Biomarker for Evaluating the Efficacy of Mutant Neoantigen Specific T Cell Combined with PD1 Antibody

+

MA25 - Precision Medicine in Advanced NSCLC

+

MA25.09 - Navigating Anlotinib Precision Therapy Through the Genetic Profiling of Circulating DNA in Non-Small Cell Lung Cancer Patients

Stay Connected